- Home
- PRAX vs GETY Comparison
PRAX vs GETY Comparison
Compare PRAX & GETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- GETY
- Stock Information
- Founded
- PRAX 2015
- GETY 1995
- Country
- PRAX United States
- GETY United States
- Employees
- PRAX N/A
- GETY N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- GETY Industrial Machinery/Components
- Sector
- PRAX Health Care
- GETY Industrials
- Exchange
- PRAX Nasdaq
- GETY Nasdaq
- Market Cap
- PRAX 599.7M
- GETY 644.9M
- IPO Year
- PRAX 2020
- GETY N/A
- Fundamental
- Price
- PRAX $38.35
- GETY $1.89
- Analyst Decision
- PRAX Strong Buy
- GETY Hold
- Analyst Count
- PRAX 10
- GETY 5
- Target Price
- PRAX $116.50
- GETY $4.60
- AVG Volume (30 Days)
- PRAX 430.8K
- GETY 573.1K
- Earning Date
- PRAX 05-02-2025
- GETY 05-12-2025
- Dividend Yield
- PRAX N/A
- GETY N/A
- EPS Growth
- PRAX N/A
- GETY 99.37
- EPS
- PRAX N/A
- GETY 0.10
- Revenue
- PRAX $8,122,000.00
- GETY $939,287,000.00
- Revenue This Year
- PRAX N/A
- GETY $2.37
- Revenue Next Year
- PRAX $789.73
- GETY $2.59
- P/E Ratio
- PRAX N/A
- GETY $19.46
- Revenue Growth
- PRAX 270.02
- GETY 2.48
- 52 Week Low
- PRAX $26.70
- GETY $1.25
- 52 Week High
- PRAX $91.83
- GETY $4.49
- Technical
- Relative Strength Index (RSI)
- PRAX 53.31
- GETY 50.81
- Support Level
- PRAX $34.89
- GETY $1.81
- Resistance Level
- PRAX $40.89
- GETY $2.01
- Average True Range (ATR)
- PRAX 2.30
- GETY 0.09
- MACD
- PRAX 0.70
- GETY 0.01
- Stochastic Oscillator
- PRAX 57.95
- GETY 36.96
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About GETY Getty Images Holdings Inc.
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.